tbuckley/cabot-search huggingface dataset:
Partnering with quintiles EEME in performing clinical research in oncology.
Authors: J. Mircheva, S. Brincat
Journal: Journal of Clinical Oncology (2010)

e13161 Background: The only oncology center on the Maltese Islands, Sir Paul Boffa Hospital, sees more than 1,400 new cases a year. Quintiles initiated operations in Malta in 2002 with the hospitals' oncology center participating in number of clinical studies to evaluate the therapeutic activity and safety of temsirolimus (in advanced breast cancer); bosutinib in a phase II breast cancer study; cediranib in colorectal cancer; neratinib in HER2 positive breast cancer, among others. Methods: The presentation will focus on the positive outcome of the collaboration between Quintiles and the Sir Paul Boffa oncology center. Results: Emphasis will be placed on the advantages for the Maltese patients—access to standard and study medications that were in some cases beyond reach; implementation of the most advance protocols of treatment and the use of modern diagnostic techniques on the background of the highest standards of GCP; and establishment of strong relationship doctor/patient, among others. As a public hospital, Sir Paul Boffa Hospital' administration has acknowledged the benefits of commercial research, as several necessary investigations, e.g., CT, MRI and isotope scans, as well as echocardiograms and blood tests, were funded. Further, clinical trial research has provided the medical staff with extensive experience recent developments in clinical oncology. The investigators' meetings were an added bonus, providing an opportunity to be part of international team. Conclusions: Sir Paul Boffa Hospital has the advantage of serving the whole country, allowing rapid patient recruitment and a perfect record of patient follow-up. Based on the good working relationship between Quintiles and the staff at Sir Paul Boffa Hospital, feasibilities were answered within 24 hours, timelines for obtaining Regulatory Approval, IP import and FPI were shortened to its reasonable maximum, the quality of the research was at its high. The understanding of the positive aspects of clinical research and the unconditional support of it by the public at large and by medical society on the Maltese Islands is one of the undisputable benefits. No significant financial relationships to disclose.
GW27-e1236 Effect of aconine on the expression of SOD and MDA in EAhy926 cells injured by homocysteine
Authors: Liu Yong, Shujie Yu, Baoshun Hao, Bin Zhou, XianGuan Yu, Dinghui Liu, Lin Wu, Min Wang, Ximei Zhang, Lin Chen, Xiaoxian Qian
Journal: Journal of the American College of Cardiology (2016)
Special Report: American Academy of Ophthalmology Task Force Recommendations for Test Methods to Assess Accommodation Produced by Intraocular Lenses
Authors: Adrian Glasser, Gene Hilmantel, Don Calogero, Scott MacRae, Samuel Masket, Walter Stark, Jack T. Holladay, Eva Rorer, Michelle E. Tarver, Tieuvi Nguyen, Malvina E. Eydelman
Journal: Ophthalmology (2016)
SH2 Domain–Containing Phosphatase-2 Is a Novel Antifibrotic Regulator in Pulmonary Fibrosis
Authors: Argyrios Tzouvelekis, Guoying Yu, Christian L. Lino Cardenas, Jose D. Herazo-Maya, Rong Wang, Tony Woolard, Yi Zhang, Koji Sakamoto, Hojin Lee, Jae-Sung Yi, Giuseppe DeIuliis, Nikolaos Xylourgidis, Farida Ahangari, Patty J. Lee, Vassilis Aidinis, Erica L. Herzog, Robert Homer, Anton M. Bennett, Naftali Kaminski
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Idiopathic pulmonary fibrosis (IPF) is a chronic fatal lung disease with dismal prognosis and no cure. The potential role of the ubiquitously expressed SH2 domain-containing tyrosine phosphatase-2 (SHP2) as a therapeutic target has not been studied in IPF.To determine the expression, mechanistic role, and potential therapeutic usefulness of SHP2 in pulmonary fibrosis.The effects of SHP2 overexpression and inhibition on fibroblast response to profibrotic stimuli were analyzed in vitro in primary human and mouse lung fibroblasts. In vivo therapeutic effects were assessed in the bleomycin model of lung fibrosis by SHP2-lentiviral administration and transgenic mice carrying a constitutively active SHP2 mutation.SHP2 was down-regulated in lungs and lung fibroblasts obtained from patients with IPF. Immunolocalization studies revealed that SHP2 was absent within fibroblastic foci. Loss of SHP2 expression or activity was sufficient to induce fibroblast-to-myofibroblast differentiation in primary human lung fibroblasts. Overexpression of constitutively active SHP2 reduced the responsiveness of fibroblasts to profibrotic stimuli, including significant reductions in cell survival and myofibroblast differentiation. SHP2 effects were mediated through deactivation of fibrosis-relevant tyrosine kinase and serine/threonine kinase signaling pathways. Mice carrying the Noonan syndrome-associated gain-of-function SHP2 mutation (SHP2D61G/+) were resistant to bleomycin-induced pulmonary fibrosis. Restoration of SHP2 levels in vivo through lentiviral delivery blunted bleomycin-induced pulmonary fibrosis.Our data suggest that SHP2 is an important regulator of fibroblast differentiation, and its loss as observed in IPF facilitates profibrotic phenotypic changes. Augmentation of SHP2 activity or expression should be investigated as a novel therapeutic strategy for IPF.
A Novel Role for Histone Deacetylase 6 (HDAC6) in the Regulation of IL-10 and Immune Tolerance Mediated by Antigen-Presenting Cells (APCs).
Authors: Fengdong Cheng, Hongwei Wang, Noreen Luetteke, Javier Pinilla, Alan Kozikowski, Edward Seto, Alejandro v Villagra, Eduardo Sotomayor
Journal: Blood (2009)
Neutrophil to lymphocyte ratio (NLR) and its effect on the prognostic value of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model for patients treated with targeted therapy (TT).
Authors: Arnoud J. Templeton, Daniel Yick Chin Heng, Toni K. Choueiri, David F. McDermott, André P Fay, Sandy Srinivas, Lauren Christine Harshman, Benoit Beuselinck, Martin Smoragiewicz, Jenny J. Kim, Jennifer J. Knox
Journal: Journal of Clinical Oncology (2014)

470 Background: The neutrophil to lymphocyte ratio (NLR) is a marker of host inflammation and appears to have prognostic value in many solid tumors. We have found in a pilot RCC study that a NLR &gt; 2.5 was predictive of a lower likelihood of response to TT on a multivariable analysis. Here we aim to explore the added value of the NLR to improve the prognostic value of the established IMDC criteria (Heng et al JCO 2009). Methods: We included patients from 7 consortium sites where NLR data was available for patients treated with TT and compared NLR cutoff &lt;= 2.5 vs. &gt;2.5 (i.e. low vs. high NLR) and adjusted using proportional hazards regression for the known poor prognostic criteria (listed in Table). Results: Data from 859 patients were included. NLR values were: Mean 4.98, Median 3.51, Mode 2.5, 95%CI 1.42 – 14.0. Using Cutoff &lt;=2.5 vs. &gt;2.5 Median overall survival (OS) is 30.4 months (95%CI 24.9-37.0, n= 237) vs. 15.7 months (95%CI 13.0-17.2, n=622); log-rank p value &lt;0.0001. If we adjust for all six IMDC poor prognosis criteria in a proportional hazards regression model: HR of death for high NLR is 1.506 (1.177-1.928) p=0.0011, demonstrating NLR is still an independent predictor of poor OS even after using IMDC criteria. Conclusions: The NLR is a simple clinical value and is independently associated with poor overall survival even after adjustment for IMDC factors, including neutrophilia. The updated data set will be presented. [Table: see text]
CTCF Mediated Enhancer and Promoter Interaction Regulates Differential Expression of TAL1 Oncogene in Normal and Malignant Hematopoiesis
Authors: Bhavita Patel, Changwang Deng, Michael Litt, Mariana St. Just Riberio, Kairong Cui, Yuanyuan Kang, Yi Qiu, Keji Zhao, Suming Huang
Journal: Blood (2012)
GW27-e1129 RSVA314 attenuates cardiac dysfunction, oxidative stress, and inflammatory in diabetic cardiomyopathy
Authors: Gan Shouyi, Hui Yu, Hong-xia Huang, Bing Li, Ling-Yong Zeng, Xiong Ge, Jun Huang, Guang-rui Feng, Liang Liu, Fei Cai, Cai-rong Li
Journal: Journal of the American College of Cardiology (2016)
TCT-531 Safety of upsizing up to 0.8 mm beyond nominal compliance chart diameters of a novel sirolimus eluting bioresorbable scaffold in porcine coronary artery model
Authors: Pawel Gasior, Yanping Cheng, Edward A. Estrada, Jenn McGregor, Kamal Razipoor, Chang Lee, Lijie Wang, Gaoke Feng, Gerard B. Conditt, Juan Granada, Greg L. Kaluza
Journal: Journal of the American College of Cardiology (2015)
Elp3 links tRNA modification to IRES-dependent translation of LEF1 to sustain metastasis in breast cancer
Authors: Sylvain Delaunay, Francesca Rapino, Lars Tharun, Zhaoli Zhou, Lukas Heukamp, Martin Termathe, Kateryna Shostak, Iva Klevernic, Alexandra Florin, Hadrien Desmecht, Christophe J. Desmet, Laurent Nguyen, Sebastian A. Leidel, Anne E. Willis, Reinhard Büttner, Alain Chariot, Pierre Close
Journal: The Journal of Experimental Medicine (2016)

Quantitative and qualitative changes in mRNA translation occur in tumor cells and support cancer progression and metastasis. Posttranscriptional modifications of transfer RNAs (tRNAs) at the wobble uridine 34 (U34) base are highly conserved and contribute to translation fidelity. Here, we show that ELP3 and CTU1/2, partner enzymes in U34 mcm5s2-tRNA modification, are up-regulated in human breast cancers and sustain metastasis. Elp3 genetic ablation strongly impaired invasion and metastasis formation in the PyMT model of invasive breast cancer. Mechanistically, ELP3 and CTU1/2 support cellular invasion through the translation of the oncoprotein DEK. As a result, DEK promotes the IRES-dependent translation of the proinvasive transcription factor LEF1. Consistently, a DEK mutant, whose codon composition is independent of U34 mcm5s2-tRNA modification, escapes the ELP3- and CTU1-dependent regulation and restores the IRES-dependent LEF1 expression. Our results demonstrate that the key role of U34 tRNA modification is to support specific translation during breast cancer progression and highlight a functional link between tRNA modification– and IRES-dependent translation during tumor cell invasion and metastasis.
TCT-324 Elevated Echocardiographic Global Calcification Score Is Associated with Increased Mortality after Percutaneous Edge-To-Edge Repair of Mitral Regurgitation Independent of Procedural Success
Authors: Reza Arsanjani, Richard Cheng, Emily Tat, Robert Siegel, Yukiko Mizutani, Shunsuke Kubo, Saibal Kar
Journal: Journal of the American College of Cardiology (2015)
Minimally important differences and risk levels for the Composite Asthma Severity Index
Authors: Rebecca Z. Krouse, Christine A. Sorkness, Jeremy J. Wildfire, Agustin Calatroni, Rebecca Gruchalla, Gurjit K. Khurana Hershey, Meyer Kattan, Andrew H. Liu, Melanie Makhija, Stephen J. Teach, Joseph B. West, Robert A. Wood, Edward M. Zoratti, Peter J. Gergen
Journal: Journal of Allergy and Clinical Immunology (2016)
Serial Analysis of Whole Blood Cell and CD3+ T-Lymphocyte Chimerism Following Allogeneic Stem Cell Transplantation with Alemtuzumab Containing Reduced-Intensity-Conditioning (RIC).
Authors: S. Tauro, R. Lovell, G. Begum, D. J. McMullan, M. J. Griffiths, F. J. Clark, M. A. Cook, P. Mahendra, D. W. Milligan, C. F. Craddock
Journal: Blood (2005)
Epigenetic Therapy with 5-Azacitidine, Valproic Acid, and ATRA in Patients with High-Risk AML or MDS: Results of the French VIVEDEP Phase II Study
Authors: Emmanuel Raffoux, Adrienne de Labarthe, Audrey Cras, Christian Recher, Pascal Turlure, Jean-Pierre Marolleau, Oumedaly Reman, Claude Gardin, Sebastien Maury, Philippe Rousselot, Jean-Valère Malfuson, Odile Maarek, Laurent Degos, Christine Chomienne, Hervé Dombret
Journal: Blood (2008)
GW27-e0982 Can left ventricular strain analysis detect significant residual mitral regurgitation post mitral clip implantation?
Authors: James Shue Min Yeh, Jian Chen, Madhu Mary Minz, Lucia Venneri, Rajdeep Khattar, Ali Vazir, Alison Duncan, Anan Daqa, Francesca Calicchio, None Mao Liu, Cesare Quarto, Rob Smith, Neil Moat, Roxy Senior, Carlo Di Mario
Journal: Journal of the American College of Cardiology (2016)
HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma
Authors: Caron Jacobson, Nadja Kopp, Jacob V. Layer, Robert A. Redd, Sebastian Tschuri, Sarah Haebe, Diederik van Bodegom, Liat Bird, Amanda L. Christie, Alexandra Christodoulou, Amy Saur, Trevor Tivey, Stefanie Zapf, Deepak Bararia, Ursula Zimber-Strobl, Scott J. Rodig, Oliver Weigert, David M. Weinstock
Journal: Blood (2016)
GW27-e0807 Rationale, design, and baseline characteristics of a randomised trial evaluating the effect of a smart phone based patient support tool on treatment duration in patients prescribed rosuvastatin in China (eHelp China)
Authors: Di Xin, Du X, Jörntén-Karlsson M, Xu Y, Guo J, Li J, Mei X, Han L, Wang J, Shen Z, Ryden A, Ahlqvist M, Sundén M, Karlson BW, Ma C
Journal: Journal of the American College of Cardiology (2016)
Lymphopenia after adjuvant radiotherapy (RT) to predict poor survival in triple-negative breast cancer (TNBC).
Authors: Anosheh Afghahi, Maya Mathur, Tina Seto, Manisha Desai, Pragati Kenkare, Kathleen C. Horst, Amar K. Das, Caroline A. Thompson, Harold S. Luft, Peter Paul Yu, Scarlett Lin Gomez, Yen Low, Nigam H Shah, Allison W. Kurian, George W. Sledge
Journal: Journal of Clinical Oncology (2015)

1069 Background: The immune system is increasingly recognized as critical in cancer development, progression, and treatment response. Intense lymphocytic infiltration in pre-treatment biopsies predicts improved survival in TNBC; lymphopenia after RT correlates with poor prognosis in other solid tumors. We investigated the prognostic impact of RT-associated lymphopenia in early-stage TNBC. Methods: Diagnostic and treatment data from electronic medical records of Stanford University Hospital (SU) and Palo Alto Medical Foundation (PAMF), a nearby community practice, were linked at an individual patient level with demographic, staging and survival data from the California Cancer Registry. A Cox proportional hazards model (adjusted for patient age, race, insurance, marital and neighborhood socioeconomic status, and for tumor stage, grade, and chemotherapy receipt) was used to analyze the relationship between immunologic measures obtainable from complete blood counts (CBC) treated as continuous variables (minimum absolute lymphocyte count [ALC], absolute neutrophil count [ANC], and white blood cell count [WBC]) and overall survival (OS). Results: 1211 TNBC patients (pts) seen at SU and/or PAMF were identified from 2000-2011; 218 pts with stage I-III TNBC received adjuvant RT and CBC within 12 months of starting radiation. 190 of these 218 pts (87.2%) received neoadjuvant or adjuvant chemotherapy. 58.3% of treated pts were lymphopenic (ALC < 1.0 K/uL) with median ALC of 0.9 (interquartile range: 0.66-1.23). On multivariable analysis, lower ALC immediately after RT was strongly associated with worse OS (hazard ratio [HR] for death with an increase of 0.1 K/uL in ALC = 0.70, 95% confidence interval [CI]: 0.55–0.91); lower ANC (HR = 0.98, 95% CI: 0.95–1.01) and WBC (HR = 0.99, 95% CI: 0.97–1.00) were not associated with OS. Conclusions: Among curable TNBC pts, a low ALC after RT was independently associated with a substantial increase in the risk of death; no such effect was observed with other blood counts. These results build on tumor-based studies implicating lymphocyte function as a key determinant of treatment response and survival, and may guide development of targeted immunotherapies for TNBC.
Mir-223 Is Dispensable for the Onset of Acute Myeloid Leukemia
Authors: Florian Kuchenbauer, Tobias Berg, Sarah M Mah, Milijana mirkovic-Hosle, Anisa Salmi, Jens Ruschmann, Andrew Muranyi, Bob Agiropoulos, Arefeh Rouhi, Daniel T Starczynowski, Michael Heuser, Donna E. Hogge, Fernando D. Camargo, Hartmut Dohner, Christian Buske, R. Keith Humphries
Journal: Blood (2010)
Diagnosis of invasive aspergillosis using Galactomannan assay in pediatric patients with cancer
Authors: M. Anjan, J. Oberoi, S. P. Yadav, A. Sachdeva
Journal: Journal of Clinical Oncology (2008)

20522 Background: Invasive aspergillosis (IA) is an important cause of increased mortality and morbidity in immunocompromised patients. Early diagnosis is difficult as microbiological culture techniques have low sensitivity and the radiological tools have low specificity. Some adult studies have concluded that serial determination of Galactomannan by sandwich Elisa (GM Assay) is a sensitive tool for the diagnosis of IA in patients at risk. Due to the paucity of data in the pediatric age group we evaluated utility of GM Assay in diagnosis of IA in pediatric cancer patients. Methods: This is a prospective study, which included high-risk pediatric cancer patients admitted with fever at Sir Ganga Ram Hospital from Oct 2006 to Dec 2007. They were receiving chemotherapy for malignancy with neutropenia <500 neutrophils/mm3 for >10 days, bone marrow transplant - allogeneic/autologous, relapsed acute lymphoblastic leukemia and acute myeloid leukemia. GM assay was done twice weekly in each episode. GM assay index >1.0 was taken as positive. CT chest/sinus and Broncho-alveolar lavage (BAL) was performed as per protocol. IA was classified as Proven, Probable, Possible and No fungus as per EORTC Guidelines. Results: A total of 95 serum samples for GM Assay were collected during 34 episodes of fever (Febrile neutropenia - 23 episodes). 34/95 (36%) GM assay serum samples were positive. 4 had proven IA, 6 had Probable IA, 3 had Possible IA and 21 had No fungus as per EORTC guidelines. 11 patients had evidence of suspected IA in CT Chest. BAL was done in 6 episodes, out of which 2 episodes had evidence of Aspergillus. The GM Assay conducted in this study had a sensitivity of 90% and specificity of 80%. It had a positive predictive value of 64% and negative predictive value of 95%. GM assay was negative in 2 episodes where Piperacillin-Tazobatum was used. Conclusion: Serial GM Assay is highly sensitive for diagnosis of IA in high-risk pediatric cancer patients. This test has a good negative predictive value in ruling out IA in immunosuppressed children. Results of GM Assay of episodes with Proven, Probable, Possible and No IA Patient case category Positive GM Negative GM Total episodes Proven IA 3 1 4 Probable IA 6 0 6 Possible IA 2 1 3 No Fungus 2 19 21 Total 13 21 34 No significant financial relationships to disclose.
The Effect of Adding Rituximab to CHOP-Based Therapy on Clinical Outcomes for Patients In Different Subgroups of DLBCL
Authors: Shenxian Qian, Daquan Gao, Pengfei Shi, Junfeng Tan, Ling Wang, Lirong Liu, Xilian Huang, Kuang Chang, Yaping Xie, Ying Xu
Journal: Blood (2010)
Dasatinib Induces a Rapid, Dose-Controllable Mobilization of Cytotoxic Lymphocytes: A Novel Immunomodulatory Effect Associated with Prolonged Therapy Responses In Advanced Leukemia.
Authors: Satu Mustjoki, Philippe Rousselot, Sari Jalkanen, Anna Kreutzman, Teresa Melo, Anna-Maria Lahesmaa, Sampsa Hautaniemi, Mathieu Molimard, Richard Smykla, Francis Lee, Jukka Vakkila, Kimmo Porkka
Journal: Blood (2010)
Bone Marrow (BM) Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated with Nilotinib
Authors: Santa Errichiello, Simona Caruso, Concetta Quintarelli, Biagio De Angelis, Novella Pugliese, Roberta Della Pepa, Barbara Izzo, Luigia Luciano, Simona Soverini, Carolina Terragna, Giovanni Martinelli, Daniela Cilloni, Giuseppe Saglio, Mario Annunziata, Giovanni Caocci, Luciano Levato, Emilio Usala, Massimo Breccia, Angelo Michele Carella, Nicola Cascavilla, Mariella D'Adda, Claudia Galimberti, Frank Giles, Andreas Hochhaus, Fabrizio Pane
Journal: Blood (2015)
Molecular Markers Predicting Clinical Outcome in Patients with Intermediate-Risk Acute Myeloid Leukemia Receiving Autologous Stem Cell Transplantation.
Authors: Jordi Esteve, Susana Kalko, Montserrat Torrebadell, Mireia Camos, Pedro Jares, Maria Rozman, Marta Pratcorona, Salut Brunet, Josep Nomdedeu, Ana Carrio, Dolors Costa, Emili Montserrat
Journal: Blood (2007)
Response to JAK 1/2 Inhibition in Patients with Corticosteroid-Refractory Acute Graft-Versus-Host Disease
Authors: Silvia Spoerl, Kristina Maas-Bauer, Mareike Verbeek, Petya Apostolova, Anna Lena Illert, Nimitha Mathew, Hendrik Poeck, Hartmut Bertz, Jürgen Finke, Christian Peschel, Justus Duyster, Robert Zeiser, Nikolas von Bubnoff
Journal: Blood (2014)
TCT-266 Predictors of Mortality in Non-Anterior ST-segment Elevation Myocardial Infarction: Insights from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial
Authors: Gennaro Giustino, Joe Dizon, Philippe Genereux, Roxana Mehran, Mario Gössl, Bernard J. Gersh, Girma M. Ayele, Gregg W. Stone
Journal: Journal of the American College of Cardiology (2015)
Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe
Authors: Christoph Lange, Raquel Duarte, Mathilde Fréchet-Jachym, Gunar Guenther, Lorenzo Guglielmetti, Ioana D. Olaru, Olena Oliveira, Rudolf Rumetshofer, Nicolas Veziris, Frank van Leth
Journal: American Journal of Respiratory and Critical Care Medicine (2016)
TCT-680 Pre-Procedural Work-up process In Patients Undergoing Transcatheter Aortic Valve Implantation: Results From The Written (WoRldwIde TAVI ExpieNce) Survey
Authors: Enrico Cerrato, Luis Nombela-Franco, Helene Eltchaninoff, Lars Søndergaard, Henrique B. Ribeiro, Marco Barbanti, Fabian Nietlispach, Peter De Jaegere, Pierfrancesco Agostoni, Pilar Jimenez-Quevedo, Ramiro Trillo, Claudio Moretti, Olaf Wendler, Gabriel Maluenda, Corrado Tamburino, Carlos Macaya, Josep Rodes-Cabau
Journal: Journal of the American College of Cardiology (2015)
Special Report: American Academy of Ophthalmology Task Force Consensus Statement for Extended Depth of Focus Intraocular Lenses
Authors: Scott MacRae, Jack T. Holladay, Adrian Glasser, Don Calogero, Gene Hilmantel, Samuel Masket, Walter Stark, Michelle E. Tarver, Tieuvi Nguyen, Malvina Eydelman
Journal: Ophthalmology (2016)
Gene Rearrangements and Other Molecular Features in Aggressive B-Cell Lymphomas of Patients with and without HIV-Infection
Authors: Maria Joao Baptista, Gustavo Tapia, Ana-Maria Muñoz-Marmol, Olga Garcia, Josep Muncunill, Maria-Jose Terol, Eva González-Barca, Pilar Miralles, Ferran Vall-Llovera, Mariano Provencio, Miriam Moreno, Juan-Manuel Sancho, Jose-Luis Mate, Evarist Feliu, Josep-Maria Ribera, Jose-Tomas Navarro
Journal: Blood (2015)
Health department warned Vote Leave campaign not to use NHS logo
Authors: Margaret McCartney
Journal: BMJ (2016)

The Vote Leave campaign in the UK referendum on membership of the European Union was repeatedly warned by the Department of Health for England not to use the NHS logo ahead of the vote, The BMJ has discovered.

Emails obtained by a GP under freedom of information legislation show that in February 2016 the department’s NHS brand and identity team issued warnings to the campaign about using the logo.1

The NHS logo was a prominent part of the Vote Leave campaign. It was displayed on leaflets delivered to homes and on the “Brexit battle bus” that toured the United Kingdom from May 2016, ahead of the referendum on 23 June. The advertisement on the side of the bus said, “We send the EU £350m a week. Let’s fund our NHS …
Incidental Meningioma Mimicking Metastasis of Prostate Adenocarcinoma in 68Ga-Labeled PSMA Ligand PET/CT
Authors: Refik Bilgin, Nurhan Ergül, Tevfik Fikret Çermik
Journal: Clinical Nuclear Medicine (2016)

A 67-year-old man with prostate adenocarcinoma underwent Ga-labeled prostate-specific membrane antigen (PSMA) ligand PET/CT for restaging due to a rising prostate-specific antigen level. Local recurrence in the prostatic region and a metastasis in the left iliac bone were detected showing high PSMA expression. A mass lesion was seen in the left orbitofrontal region with high Ga PSMA uptake. The successive MRI confirmed that the lesion was consistent with meningioma.